Evidence boundary
Current labels do not publish a swelling-only rate
The June 2026 Wegovy label reports grouped injection-site reactions in 1.4% of treated adults and 1% of placebo-treated adults in weight-reduction trials; the group includes itching, redness, inflammation, firmness, and irritation. Current Ozempic trials report grouped local discomfort or redness in 0.2% of treated patients. Current Zepbound trials report grouped injection-site reactions in 6%, 8%, and 8% at the 5 mg, 10 mg, and 15 mg doses versus 2% with placebo, while current Mounjaro adult placebo-controlled trials report grouped reactions in 3.2% versus 0.4%. None of these figures is a stand-alone swelling rate, expected diameter, or duration cutoff.
- Do not say that each patient counted in a grouped injection-site category had swelling; the labels combine different local terms and definitions.
- Do not compare grouped percentages as proof that one GLP-1 medicine is less likely to cause swelling because products, populations, doses, and trial definitions differ.
- A trial table cannot determine whether one swollen area reflects local irritation, allergy, infection, bleeding, tissue injury, a supply issue, or another cause.
Local versus systemic swelling
A swollen spot and facial or throat swelling are different safety questions
A localized area near an injection should not be treated as equivalent to swelling of the face, lips, tongue, or throat. Current semaglutide and tirzepatide labels warn about serious hypersensitivity reactions, including anaphylaxis and angioedema. Widespread hives, wheezing, throat tightness, trouble breathing or swallowing, fainting, confusion, or rapidly developing facial or tongue swelling can require emergency care. A photo or symptom checklist cannot rule out serious allergy.
- Call emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, or a rapidly developing widespread reaction.
- Do not use a later dose as a test or start an antihistamine, steroid, or other self-treatment plan to keep treatment on schedule without clinical guidance.
- Tell the care team about prior medication or injection reactions, anaphylaxis, eczema or other skin disease, and any new medicine, supplement, adhesive, cleanser, or topical exposure.
Trend and local warning signs
Border, warmth, pain, drainage, and fever matter more than one snapshot
Useful details include how soon swelling appeared, its location and approximate size, whether the edge is stable or expanding, and whether redness, warmth, pain, firmness, itching, bruising, drainage, red streaks, fever, blistering, darkening, numbness, or skin breakdown is present. Increasing warmth or pain, rapid spread, pus, streaking, fever, or feeling acutely unwell can require prompt in-person assessment for infection or another local complication. Severe or disproportionate pain, color change, blistering, or skin breakdown also should not be managed through a seller chat or forum.
- Use a dated photo with a size reference when the care team requests one; lighting and skin tone can make color alone misleading.
- Seek prompt local assessment for rapidly spreading redness or swelling, severe or escalating pain, pus, red streaks, fever or chills, blistering, darkening, numbness, or skin breakdown.
- Contact the prescriber for persistent, recurrent, enlarging, unusually painful, or treatment-limiting swelling even when emergency features are absent.
Product and site review
Match the symptom to the exact injection and what touched the skin
Wegovy also has a labeled once-daily oral tablet, which has no injection site; an injection-site symptom must be matched to an injectable presentation. For any injectable product, record the active ingredient, brand or compounded status, device or vial, concentration, site, supplies, pharmacy, refill or lot details, storage, and shipment history. MedlinePlus subcutaneous-injection guidance says the chosen site should not already have redness, swelling, scarring, bruising, or other damage and should be changed between injections. Follow the instructions supplied with the exact product rather than using this symptom guide as an injection tutorial.
- Report whether the skin was already swollen, red, bruised, scarred, hardened, irritated, recently shaved, or affected by eczema, infection, or another condition.
- Note any new needle, device, alcohol prep, adhesive, bandage, cleanser, lotion, refill, concentration, inactive ingredient, caregiver help, shipment, or storage concern.
- Do not squeeze, puncture, vigorously massage, inject into, or cover a concerning area with leftover prescription creams or home remedies.
Compounded-product boundary
A compounded vial does not inherit a branded product’s reaction rate
Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved finished drug products with product-specific labels. A patient-specific compounded semaglutide or tirzepatide prescription is not an FDA-approved finished drug product and can differ in presentation, concentration, inactive ingredients, container, supplies, storage directions, and beyond-use date. Branded labels can provide context, but they cannot validate a compounded preparation or establish why one injection site is swollen.
- Confirm the prescriber, dispensing pharmacy, active ingredient, route, concentration, patient label, supplies, storage history, and adverse-event contact.
- Ask the dispensing pharmacy about a changed label or concentration, damaged package, delayed or warm shipment, cloudy or discolored solution, particles, or uncertain storage before another use decision.
- Avoid research-use vials, counterfeit pens, unlabeled mixtures, copied syringe conversions, and sellers that skip prescription-first clinician review.